title: Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation.
abstract: Recombinant human erythropoietin (rHu-EPO) in the treatment of renal anemia might predispose to an increased risk of thrombotic complications. In an attempt to comprehend the involvement of the physiologic inhibitors of coagulation in this process, we studied 2 groups of hemodialysis patients. Group I included 21 patients receiving a starting dose of 90 IU/kg/week s.c., and group II included 17 patients without rHu-EPO. The following coagulation tests were performed before rHu-EPO treatment, and after 1, 6 and 12 months: prothrombin time; activated partial fistula thromboplastin time; fibrinogen; plasminogen activity; antithrombin III activity; protein C activity; total and free protein S antigens, and C4b binding protein. Only the latter three parameters were changed in group 1, while high baseline levels of protein S antigens were found in both groups. A decrease in total and free protein S was observed within 1 month of treatment. At the 6th month total protein S returned to near pretreatment values, whereas a significant fall in free protein S (p = 0.007) was observed. All three parameters returned to near baseline values by 12 months. These results suggest that protein S activity can be altered at the beginning of EPO therapy, a change that under favoring circumstances might contribute to the thrombotic events reported during the early phase of rHu-EPO treatment.
authors.affiliation: Service de Néphrologie, Hôpital Bichat, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Jaar
authors.forename: A
authors.initials: A
authors.lastname: Denis
authors.forename: B
authors.initials: B
authors.lastname: Viron
authors.forename: E
authors.initials: E
authors.lastname: Verdy
authors.forename: F
authors.initials: F
authors.lastname: Chamma
authors.forename: P
authors.initials: P
authors.lastname: Siohan
authors.forename: F
authors.initials: F
authors.lastname: Mignon
mesh_terms: D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D000990:Antithrombin III / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects*; D002408:Catheters, Indwelling; D015935:Complement C4b / Q000037:antagonists & inhibitors; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010958:Plasminogen / Q000187:drug effects; D011486:Protein C / Q000187:drug effects; D017293:Protein S / Q000187:drug effects / Q000276:immunology; D011517:Prothrombin Time; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D011486:Protein C; D017293:Protein S; D011994:Recombinant Proteins; D004921:Erythropoietin; D015935:Complement C4b; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen